Expansion of immunodominant clonotypes in bone marrow failure patients
Patient no. . | Diagnosis . | VB . | CDR3 . | JB . | % clonal expansion . |
|---|---|---|---|---|---|
| 1 | MDS/LGL | 14 | ASSLLTKTGSYEQE | 2.5 | 100 |
| 2 | MDS/LGL | 9 | ASSLPGTPTE | 1.1 | 100 |
| 3 | MDS | 4 | AALMPPQPRETP | 2.5 | Direct |
| 4 | MDS | 11 | ASSGTGSYE | 2.7 | 63 |
| 5 | MDS | 7 | APAAKMERLT | 2.1 | Direct |
| 5 | MDS | 1 | ASSSELTFRGDT | 2.3 | Direct |
| 6 | MDS | 23 | ATSAGSE | 2.7 | Direct |
| 7 | MDS | 23 | ASSLTDT | 2.2 | 100 |
| 8 | MDS | 8 | ASSFAPMTSGGALDT | 2.3 | 60 |
| 8 | MDS | 21 | ASSPRLAGALETPWET | 2.3 | 50 |
| 9 | MDS | 3 | ASSLGDVNQPQH | 1.5 | 100 |
| 10 | MDS | 3 | ASSKPGSPYQEQ | 2.5 | 50 |
| 10 | MDS | 13 | ASSSLEGGQGN | 2.3 | 36 |
| 11 | MDS | 21 | ASSPGWDRGLE | 2.5 | 100 |
| 12 | MDS | 21 | ASSFRLAGANNE | 2.1 | 67 |
| 13 | MDS | 4 | AALGPPTMSS | 2.5 | Direct |
| 13 | MDS | 1 | ASSLGQGSSYEE | 2.5 | Direct |
| 13 | MDS | 8 | ASSLPSVAN | 2.2 | Direct |
| 14 | MDS | 18 | ASSTGENTG | 2.2 | 75 |
| 30 | AA | 7 | ASSPPGGARMGE | 2.5 | 100 |
| 30 | AA | 16 | ASSQDLAGGPRRET | 2.3 | 56 |
| 30 | AA | 16 | ASSRGRHTDT | 2.3 | 33 |
| 30 | AA | 1 | ASSVGHGVNE | 1.4 | 100 |
| 31 | AA | 18 | ASSPTSAAYG | 1.2 | 70 |
| 31 | AA | 5 | ASSSANYRTDT | 1.1 | 90 |
| 32 | AA | 23 | ASSSHITDT | 2.3 | 80 |
| 33 | AA | 5 | ASSLDRASTPE | 1.1 | 100 |
| 33 | AA | 9 | ASSPANGLADAYE | 2.7 | 50 |
| 35 | AA | 12 | ASSEITEPG | 2.2 | 50 |
| 36 | AA | 15 | ATSDYDREVGDT | 2.3 | 40 |
| 36 | AA | 3 | ASAGTGGNE | 1.4 | 33 |
| 37 | AA | 13 | ASSSIGRTSTDT | 2.3 | 36 |
| 38 | AA | 13 | ASSYYG | 1.2 | 25 |
| 39 | AA | 6 | ASSSPPVDT | 2.3 | 77 |
| 39 | AA | 15 | ATSDLASFNTG | 2.2 | 46 |
| 40 | AA | 22 | ASKWEQGVGNTE | 1.1 | 93 |
| 40 | AA | 23 | ASSFPGQGINE | 2.1 | 100 |
| 41 | AA | 15 | ATGTGDTDT | 2.3 | 33 |
| 41 | AA | 24 | ATSRVGGE | 2.5 | 50 |
| 42 | AA | 7 | ASSTGAYPYNE | 2.1 | 70 |
| 43 | AA | 3 | ASSFRDREETNQPQH | 1.5 | 27 |
| 44 | AA | 2 | CSASFRVE | 2.5 | 57 |
| 20 | PNH | 20 | ASSWKPPPIPYE | 2.7 | 33 |
| 20 | PNH | 8 | ASSLAVAQE | 2.5 | 67 |
| 21 | PNH | 8 | PLTGLTLSE | 2.5 | 36 |
| 22 | PNH | 13 | ASSRRANTG | 2.2 | 30 |
| 22 | PNH | 1 | ASSAAGVKE | 2.5 | 100 |
| 23 | PNH | 13 | ASSSSGSYNE | 2.1 | 60 |
| 24 | PNH | 3 | ASGQRGGA | 2.4 | 61 |
| 25 | PNH | 3 | ASSWTGYE | 2.7 | 76 |
| 25 | PNH | 13 | ASSYGGGQPQFH | 1.5 | 55 |
| 16 | MDS | 4 | ASSPRGTF | 1.5 | 67 |
| 29 | AA | 12 | AISLGGELFF | 2.2 | 50 |
| 29 | AA | 17 | ASSRGLADTDTQYF | 2.3 | 67 |
Patient no. . | Diagnosis . | VB . | CDR3 . | JB . | % clonal expansion . |
|---|---|---|---|---|---|
| 1 | MDS/LGL | 14 | ASSLLTKTGSYEQE | 2.5 | 100 |
| 2 | MDS/LGL | 9 | ASSLPGTPTE | 1.1 | 100 |
| 3 | MDS | 4 | AALMPPQPRETP | 2.5 | Direct |
| 4 | MDS | 11 | ASSGTGSYE | 2.7 | 63 |
| 5 | MDS | 7 | APAAKMERLT | 2.1 | Direct |
| 5 | MDS | 1 | ASSSELTFRGDT | 2.3 | Direct |
| 6 | MDS | 23 | ATSAGSE | 2.7 | Direct |
| 7 | MDS | 23 | ASSLTDT | 2.2 | 100 |
| 8 | MDS | 8 | ASSFAPMTSGGALDT | 2.3 | 60 |
| 8 | MDS | 21 | ASSPRLAGALETPWET | 2.3 | 50 |
| 9 | MDS | 3 | ASSLGDVNQPQH | 1.5 | 100 |
| 10 | MDS | 3 | ASSKPGSPYQEQ | 2.5 | 50 |
| 10 | MDS | 13 | ASSSLEGGQGN | 2.3 | 36 |
| 11 | MDS | 21 | ASSPGWDRGLE | 2.5 | 100 |
| 12 | MDS | 21 | ASSFRLAGANNE | 2.1 | 67 |
| 13 | MDS | 4 | AALGPPTMSS | 2.5 | Direct |
| 13 | MDS | 1 | ASSLGQGSSYEE | 2.5 | Direct |
| 13 | MDS | 8 | ASSLPSVAN | 2.2 | Direct |
| 14 | MDS | 18 | ASSTGENTG | 2.2 | 75 |
| 30 | AA | 7 | ASSPPGGARMGE | 2.5 | 100 |
| 30 | AA | 16 | ASSQDLAGGPRRET | 2.3 | 56 |
| 30 | AA | 16 | ASSRGRHTDT | 2.3 | 33 |
| 30 | AA | 1 | ASSVGHGVNE | 1.4 | 100 |
| 31 | AA | 18 | ASSPTSAAYG | 1.2 | 70 |
| 31 | AA | 5 | ASSSANYRTDT | 1.1 | 90 |
| 32 | AA | 23 | ASSSHITDT | 2.3 | 80 |
| 33 | AA | 5 | ASSLDRASTPE | 1.1 | 100 |
| 33 | AA | 9 | ASSPANGLADAYE | 2.7 | 50 |
| 35 | AA | 12 | ASSEITEPG | 2.2 | 50 |
| 36 | AA | 15 | ATSDYDREVGDT | 2.3 | 40 |
| 36 | AA | 3 | ASAGTGGNE | 1.4 | 33 |
| 37 | AA | 13 | ASSSIGRTSTDT | 2.3 | 36 |
| 38 | AA | 13 | ASSYYG | 1.2 | 25 |
| 39 | AA | 6 | ASSSPPVDT | 2.3 | 77 |
| 39 | AA | 15 | ATSDLASFNTG | 2.2 | 46 |
| 40 | AA | 22 | ASKWEQGVGNTE | 1.1 | 93 |
| 40 | AA | 23 | ASSFPGQGINE | 2.1 | 100 |
| 41 | AA | 15 | ATGTGDTDT | 2.3 | 33 |
| 41 | AA | 24 | ATSRVGGE | 2.5 | 50 |
| 42 | AA | 7 | ASSTGAYPYNE | 2.1 | 70 |
| 43 | AA | 3 | ASSFRDREETNQPQH | 1.5 | 27 |
| 44 | AA | 2 | CSASFRVE | 2.5 | 57 |
| 20 | PNH | 20 | ASSWKPPPIPYE | 2.7 | 33 |
| 20 | PNH | 8 | ASSLAVAQE | 2.5 | 67 |
| 21 | PNH | 8 | PLTGLTLSE | 2.5 | 36 |
| 22 | PNH | 13 | ASSRRANTG | 2.2 | 30 |
| 22 | PNH | 1 | ASSAAGVKE | 2.5 | 100 |
| 23 | PNH | 13 | ASSSSGSYNE | 2.1 | 60 |
| 24 | PNH | 3 | ASGQRGGA | 2.4 | 61 |
| 25 | PNH | 3 | ASSWTGYE | 2.7 | 76 |
| 25 | PNH | 13 | ASSYGGGQPQFH | 1.5 | 55 |
| 16 | MDS | 4 | ASSPRGTF | 1.5 | 67 |
| 29 | AA | 12 | AISLGGELFF | 2.2 | 50 |
| 29 | AA | 17 | ASSRGLADTDTQYF | 2.3 | 67 |
VB indicates variable region of the T-cell receptor beta chain (TCR); CDR3, complementarity determining region 3 of the TCR beta chain; JB, joining region of the TCR; AA, aplastic anemia; and direct, direct sequencing of the amplification product